Skip to main content
    I

    Iovance Biotherapeutics Inc (IOVA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.53
    -0.02 (-0.26%)

    Market Cap: $3.59B

    Last updated: Nov 17, 2026 at 4:35 PM ET

    Iovance Biotherapeutics Inc (IOVA) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Iovance Biotherapeutics (IOVA) has a market cap of $3.59B and an enterprise value of $3.53B. Its share count is up 25.24% from a year earlier. It kept -58.19% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 1.61% below the market cap, as cash exceeds debt.

    Market Cap$3.59B
    Enterprise Value$3.53B
    Latest price (Nov 17, 2026)$7.53

    Key Dates

    The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 22, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 1.27% in the quarter ended Sep 30, 2026 and grew 22.61% a year over 2 years.

    Shares Outstanding455.92M
    Shares Change (YoY)+25.24%
    Shares Change (QoQ)+1.27%
    Share Count Growth (2Y CAGR)+22.61%

    Valuation Ratios

    Sales and book value multiples are 9.1x and 4.2x.

    P/S Ratio9.1x
    Forward P/S8.6x
    P/B Ratio4.2x
    P/TBV Ratio6.2x

    Price Statistics

    The stock is up 204.86% over 52 weeks and trades 33.30% below its 50-day average.

    Beta (1Y)1.63
    52-Week Change+204.86%
    1-Month Change-47.01%
    3-Month Change-5.76%
    6-Month Change+117.63%
    5-Year Change-65.12%
    10-Year Change+35.68%
    Total Return (1Y)+204.86%
    Total Return (3Y CAGR)+14.24%
    Total Return (5Y CAGR)-16.95%
    Return vs SPY (1Y)+197.05%
    Max Drawdown (1Y)-49.33%
    Max Drawdown (3Y)-90.50%
    Sharpe Ratio (1Y)1.07
    Correlation with SPY (1Y)0.21
    50-Day Average$11.29
    200-Day Average$6.16
    52-Week Range$2.08 to $15.37
    RSI (14 Days)31.8
    Average Volume (20 Days)15.33M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 5.20x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio5.20x
    Quick Ratio4.67x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -27.14% over the last 12 months, against a 5-year average of -63.72%.

    Return on Equity (ROE)-27.14%
    Return on Assets (ROA)-22.25%
    ROE (5Y Average)-63.72%
    ROA (5Y Average)-48.85%
    ROIC (5Y Average)-56.25%
    Asset Turnover0.40x
    Inventory Turnover2.93x
    Receivables Turnover3.62x
    Cash Conversion Cycle171 days

    Scores

    IOVA has an Altman Z-Score of 7.56, in the safe zone above 2.99, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score7.56
    Altman Z ZoneSafe
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $378.98M over the last 12 months is up 51.34% from the 12 months before.

    Revenue$378.98M
    Revenue Growth (YoY)+51.34%
    Gross Profit$216.56M
    Operating Income-$230.38M
    Pretax Income-$221.78M
    Net Income-$220.53M
    EBITDA-$192.16M
    Reported EPS (TTM)-$0.53

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 81.99% of the $991.21M in total assets.

    Cash and Equivalents$57.93M
    Total Debt$0
    Net Cash$57.93M
    Net Cash Per Share$0.13
    Working Capital$443.86M
    Shareholder Equity$812.66M
    Book Value Per Share$1.78
    Tangible Book Value$553.46M
    Tangible Book Per Share$1.21
    Total Assets$991.21M
    Total Liabilities$178.55M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $26.11M of capital spending, operating cash flow left -$216.06M of free cash flow.

    Operating Cash Flow-$189.95M
    Capital Expenditures$26.11M
    Free Cash Flow-$216.06M
    FCF Per Share-$0.48
    Depreciation and Amortization$38.22M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -60.79%.

    Gross Margin57.14%
    Operating Margin-60.79%
    Pretax Margin-58.52%
    Net Margin-58.19%
    EBITDA Margin-50.70%
    FCF Margin-57.01%

    Dividends and Yields

    IOVA does not pay a dividend. Its free cash flow yield is -6.29%.

    FCF Yield-6.29%
    Buyback Yield-8.55%
    Shareholder Yield-8.55%

    Stock Splits

    The last split was a 1-for-100 reverse split on Sep 26, 2013.

    Last Split DateSep 26, 2013
    Split TypeReverse split
    Split Ratio1:100

    Peer Position

    Against 9 similar companies, IOVA has the 7th highest P/S.

    P/S Ratio9.1x vs 13.1x median
    Revenue Growth (Trailing 4 Quarters, YoY)+51.34% vs +29.42% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 50.12% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+50.12%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About IOVA

    What is IOVA's market cap?

    Iovance Biotherapeutics has a market cap of $3.59B. Its enterprise value, which adds debt and subtracts cash, is $3.53B.

    How many shares of IOVA are outstanding?

    Iovance Biotherapeutics has 455.92M shares outstanding. The count is up 25.24% from a year earlier.

    Does IOVA pay a dividend?

    No. Iovance Biotherapeutics does not pay a dividend.

    How much debt does IOVA have?

    Iovance Biotherapeutics has $0 of total debt and $57.93M of cash and equivalents, a net cash position of $57.93M.